compound 991 Search Results


92
TargetMol compound 991
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Compound 991, supplied by TargetMol, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 991/product/TargetMol
Average 92 stars, based on 1 article reviews
compound 991 - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

90
SpiroChem ag adenosine monophosphate-activated protein kinase (ampk) activator compound 991 (ex229
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Adenosine Monophosphate Activated Protein Kinase (Ampk) Activator Compound 991 (Ex229, supplied by SpiroChem ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adenosine monophosphate-activated protein kinase (ampk) activator compound 991 (ex229/product/SpiroChem ag
Average 90 stars, based on 1 article reviews
adenosine monophosphate-activated protein kinase (ampk) activator compound 991 (ex229 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Aobious Inc compound 991
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Compound 991, supplied by Aobious Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 991/product/Aobious Inc
Average 90 stars, based on 1 article reviews
compound 991 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
AstraZeneca ltd compound 991
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Compound 991, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 991/product/AstraZeneca ltd
Average 90 stars, based on 1 article reviews
compound 991 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Aobious Inc compound 991 aob8150
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Compound 991 Aob8150, supplied by Aobious Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 991 aob8150/product/Aobious Inc
Average 90 stars, based on 1 article reviews
compound 991 aob8150 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Metabasis Therapeutics cyclic benzimidazole derivative compound 991
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Cyclic Benzimidazole Derivative Compound 991, supplied by Metabasis Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyclic benzimidazole derivative compound 991/product/Metabasis Therapeutics
Average 90 stars, based on 1 article reviews
cyclic benzimidazole derivative compound 991 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
SpiroChem ag compound 991
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Compound 991, supplied by SpiroChem ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 991/product/SpiroChem ag
Average 90 stars, based on 1 article reviews
compound 991 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Aobious Inc ampk activator ex229 (compound 991)
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Ampk Activator Ex229 (Compound 991), supplied by Aobious Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ampk activator ex229 (compound 991)/product/Aobious Inc
Average 90 stars, based on 1 article reviews
ampk activator ex229 (compound 991) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
LC Laboratories compound 991
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Compound 991, supplied by LC Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 991/product/LC Laboratories
Average 90 stars, based on 1 article reviews
compound 991 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Adooq Bioscience LLC compound 991
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Compound 991, supplied by Adooq Bioscience LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 991/product/Adooq Bioscience LLC
Average 90 stars, based on 1 article reviews
compound 991 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Metabasis Therapeutics compound 991
(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) <t>Compound</t> <t>991</t> (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).
Compound 991, supplied by Metabasis Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 991/product/Metabasis Therapeutics
Average 90 stars, based on 1 article reviews
compound 991 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

N/A
Informationex229 (compound 991) EX229 (compound 991) is a potent AMPK activator that is 5-10-fold more potent than A769662 in activating AMPK.TargetsAMPKIn vitroEX229 activates AMPK in incubated rat epitrochlearis skeletal muscle and incubation of rat skeletal
  Buy from Supplier

Image Search Results


(a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) Compound 991 (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).

Journal: Nature

Article Title: CRISPR screens decode cancer cell pathways that trigger γδ T cell detection

doi: 10.1038/s41586-023-06482-x

Figure Lengend Snippet: (a) Schematic of OXPHOS, inhibitor targets, and genetic KOs. (b) Surface BTN3A MFI in Daudi-Cas9 KOs cultured in different glucose concentrations for 3 days in RPMI (no glucose, no pyruvate). Normalized to cells grown without glucose (0 g/L). (c, d) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with vehicles (DMSO, ethanol) or OXPHOS inhibitors of (c) Complex I (rotenone), Complex V (oligomycin A), mitochondrial membrane potential (FCCP), and (d) Complex III (antimycin A) for 72 hours in complete RPMI. (e-g) Surface BTN3A MFI in WT Daudi-Cas9 cells cultured with (e) 2-DG, (f) AICAR, and (g) Compound 991 (C991) or equivalent amount of DMSO (vehicle) for 72 hours in complete RPMI. (h) Surface BTN3A MFI in patient-derived breast cancer organoids and Daudi cells cultured for 3 days with pamidronate and AICAR, C991, or DMSO. (i) Surface BTN3A MFI in WT Daudi-Cas9 cells co-treated with an OXPHOS/glycolysis inhibitor and increasing amounts of Compound C (CC, AMPK inhibitor). (b) n=4 per condition, data combined from two independent experiments, each individually normalized. (c) n=4 per condition, data combined from two independent experiments. (d) n=3 per condition, representative data from one of two experiments. (e, f) n=3 per condition, representative data from one of three independent experiments. (g) n=3 per condition, representative data from one of two independent experiments. (h) n=5, data combined from two independent experiments. (i) n=3 per condition, representative data from one of three independent experiments. (b, e, f, h) One-way ANOVA comparison to the zero or control treatment condition with Dunnett’s multiple comparisons test. (c) Two-tailed unpaired Student’s t test with FDR adjustment for the tested concentrations (1.25-20 μM). (d, g) Two-tailed unpaired Student’s t test with Bonferroni correction. (b-i) Mean ± SD. p<0.0001 (****), p<0.001 (***), p<0.01 (**), p<0.05 (*).

Article Snippet: For 4 days prior to the co-culture, Daudi cells were cultured in complete RPMI and PDOs were cultured in BME for 4 days in the presence of 10 μM pamidronate and either 500 μM AICAR (Merck) or 40 μM Compound 991 (TargetMol).

Techniques: Cell Culture, Membrane, Derivative Assay, Comparison, Control, Two Tailed Test

(a) G115 clone Vγ9Vδ2 TCR tetramer staining MFI of WT Daudi-Cas9 cells treated with 80 μM C991 (DMSO), DMSO (vehicle), 0.5 mM AICAR (aqueous), or without treatment for 72 hours. Two-tailed unpaired Student’s t test. (b) Vγ4Vδ1 TCR (clone DP10.7) tetramer staining fluorescence (MFI) of Daudi-Cas9 KO cells treated with 80 μM C991 (DMSO), DMSO (vehicle), 0.5 mM AICAR (aqueous), or water for 72 hours. This staining with a tetramer of an irrelevant γδTCR clone defines the background for Vγ9Vδ2 TCR tetramer staining in Figure 4a. (c) qPCR data for BTN2A1, BTN3A1, and BTN3A2 transcripts in Daudi-Cas9 cells treated with C991, internally normalized to ACTB transcripts and normalized to DMSO (vehicle)-treated cells. Two-tailed unpaired Student’s t test. (d) IgG1κ isotype control staining in Daudi-Cas9 KO cells treated with 80 μM Compound 991 (DMSO), DMSO (vehicle), 0.5 mM AICAR (aqueous), or water (vehicle) treatment for 72 hours. (e) Survival of eGFP+ Daudi cells treated for 3 days with AICAR or water prior to co-culture (E:T 2:1) with primary Vγ9Vδ2 T cells in the presence of an anti-BTN3A antibody (clone 103.2). Cells were quantified using real-time quantitative live-cell imaging (Incucyte). Survival was normalized to Daudi cells cultured without T cells. (a) n=4 per condition, representative data from one of two independent experiments. (b) n=3 per condition, representative data from one of two independent experiments. (c) n=4 per condition, representative data from one of three independent experiments. (d) n=3, representative data from one of two independent experiments. (e) n=4 per condition. (a-e) Mean ± SD. p<0.0001 (****). Source Data files provided for Figures 2, ​,3,3, ​,4,4, and Extended Data Figures 1, ​,4,4, ​,7,7, ​,8,8, ​,9,9, and ​and1010.

Journal: Nature

Article Title: CRISPR screens decode cancer cell pathways that trigger γδ T cell detection

doi: 10.1038/s41586-023-06482-x

Figure Lengend Snippet: (a) G115 clone Vγ9Vδ2 TCR tetramer staining MFI of WT Daudi-Cas9 cells treated with 80 μM C991 (DMSO), DMSO (vehicle), 0.5 mM AICAR (aqueous), or without treatment for 72 hours. Two-tailed unpaired Student’s t test. (b) Vγ4Vδ1 TCR (clone DP10.7) tetramer staining fluorescence (MFI) of Daudi-Cas9 KO cells treated with 80 μM C991 (DMSO), DMSO (vehicle), 0.5 mM AICAR (aqueous), or water for 72 hours. This staining with a tetramer of an irrelevant γδTCR clone defines the background for Vγ9Vδ2 TCR tetramer staining in Figure 4a. (c) qPCR data for BTN2A1, BTN3A1, and BTN3A2 transcripts in Daudi-Cas9 cells treated with C991, internally normalized to ACTB transcripts and normalized to DMSO (vehicle)-treated cells. Two-tailed unpaired Student’s t test. (d) IgG1κ isotype control staining in Daudi-Cas9 KO cells treated with 80 μM Compound 991 (DMSO), DMSO (vehicle), 0.5 mM AICAR (aqueous), or water (vehicle) treatment for 72 hours. (e) Survival of eGFP+ Daudi cells treated for 3 days with AICAR or water prior to co-culture (E:T 2:1) with primary Vγ9Vδ2 T cells in the presence of an anti-BTN3A antibody (clone 103.2). Cells were quantified using real-time quantitative live-cell imaging (Incucyte). Survival was normalized to Daudi cells cultured without T cells. (a) n=4 per condition, representative data from one of two independent experiments. (b) n=3 per condition, representative data from one of two independent experiments. (c) n=4 per condition, representative data from one of three independent experiments. (d) n=3, representative data from one of two independent experiments. (e) n=4 per condition. (a-e) Mean ± SD. p<0.0001 (****). Source Data files provided for Figures 2, ​,3,3, ​,4,4, and Extended Data Figures 1, ​,4,4, ​,7,7, ​,8,8, ​,9,9, and ​and1010.

Article Snippet: For 4 days prior to the co-culture, Daudi cells were cultured in complete RPMI and PDOs were cultured in BME for 4 days in the presence of 10 μM pamidronate and either 500 μM AICAR (Merck) or 40 μM Compound 991 (TargetMol).

Techniques: Staining, Two Tailed Test, Fluorescence, Control, Co-Culture Assay, Live Cell Imaging, Cell Culture